Eli Lilly and Company (NYSE:LLY) is one of the 14 Best US Stocks to Buy for Long Term, with Guggenheim maintaining a Buy rating and raising the price target to $1,163 after an impressive year in 2025.

Eli Lilly (LLY) saw exceptional growth, with revenue reaching $17.6 billion in Q3 of 2025, a 53.8% increase from the previous year, driven by drugs like Mounjaro and Zepbound.

The company’s weight loss drug market strength, potential weight loss pill orforglipron, and positive late-stage trial results have positioned Eli Lilly (LLY) for continued success and regulatory approval.

Eli Lilly and Company (NYSE:LLY) is a multinational pharmaceutical company known for discovering and marketing a wide range of pharmaceuticals, including drugs like Mounjaro and Zepbound.

While Eli Lilly (LLY) shows promise as an investment, some believe other AI stocks offer greater upside potential with less downside risk, especially those poised to benefit from Trump-era tariffs and the onshoring trend.

Read more at Yahoo Finance: Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year”